Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PBRM1 |
Variant | loss |
Impact List | unknown |
Protein Effect | loss of function |
Gene Variant Descriptions | PBRM1 loss indicates loss of the PBRM1 gene, mRNA, and protein. |
Associated Drug Resistance | |
Category Variants Paths |
PBRM1 mutant PBRM1 inact mut PBRM1 loss |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PBRM1 loss | melanoma | sensitive | unspecified CTLA4 antibody + unspecified PD-1 antibody | Preclinical - Cell line xenograft | Actionable | In a preclinical study, knocking-out PBRM1 in melanoma cells sensitized cells to immune therapy consisted of anti-CTLA4 and anti-PD-1 antibodies in culture and in cell line xenograft models, potentially due to increased sensitivity to T cell-mediated cytotoxicity and a favorable tumor microenvironment (PMID: 29301958). | 29301958 |
PBRM1 loss | lung cancer | sensitive | PRT1419 + Sunitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of PRT1419 and Sutent (sunitinib) inhibited tumor growth and tumor re-growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625). | 38371625 |
PBRM1 loss | lung cancer | sensitive | PRT2527 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PRT2527 inhibited tumor growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625). | 38371625 |
PBRM1 loss | lung cancer | sensitive | PRT2527 + Sunitinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of PRT2527 and Sutent (sunitinib) inhibited tumor growth and tumor re-growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625). | 38371625 |